You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ctDNA negative

Showing 1 - 25 of 9,461
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.

Recruiting
  • Breast Cancer Female
  • +4 more
    • Ho Chi Minh City, Vietnam
    • +1 more
    Oct 16, 2023

    Breast Cancer Trial (Giredestrant, Abemaciclib, Inavolisib)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Feb 1, 2023

    Patient Decision Making in Early Stage Breast Cancer:Conjoint

    Recruiting
    • Triple Negative Breast Cancer
      • Indianapolis, Indiana
        Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
      Feb 14, 2023

      ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • NGS and ctDNA-MRD detection
      • Changsha, Hunan, China
        Department of Thoracic Surgery, Second Xiangya Hospital of Centr
      Apr 18, 2023

      Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Seoul (exosome and ctDNA evaluation)

      Active, not recruiting
      • Triple Negative Breast Cancer
      • HER2-positive Breast Cancer
      • exosome and ctDNA evaluation
      • Seoul, Korea, Republic of
        Ji-Yeon Kim
      Jul 13, 2023

      Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma Trial in Nashville (Biospecimen

      Not yet recruiting
      • Metastatic HER2-Negative Breast Carcinoma
      • Metastatic Triple-Negative Breast Carcinoma
      • Biospecimen Collection
      • +3 more
      • Nashville, Tennessee
        Vanderbilt University/Ingram Cancer Center
      Mar 3, 2023

      ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer Trial (Elacestrant, Tamoxifen, Letrozole 2.5mg)

      Not yet recruiting
      • ER-positive Breast Cancer
      • +3 more
      • (no location specified)
      Aug 22, 2022

      Checkpoint Inhibitors in Triple Negative Breast

      Recruiting
      • Triple Negative Breast Cancer
      • Whole Genome Sequencing
      • +7 more
      • Barcelona, Spain
        Vall d'Hebron Institute of Oncology
      Jun 20, 2023

      Potential Clinical Utilities of Circulating Tumor DNA in

      Not yet recruiting
      • Gastric Cancer
      • Circulating Tumor DNA (ctDNA)
        • (no location specified)
        Aug 21, 2022

        Significance of MRD After Surgery in Driver Gene-positive and

        Enrolling by invitation
        • NSCLC MRD ctDNA
          • Shenzhen, China
            ShenzhenPH
          Jun 30, 2022

          Triple Negative Breast Cancer, Breast Cancer Trial in Stanford (Capecitabine)

          Recruiting
          • Triple Negative Breast Cancer
          • Breast Cancer
          • Stanford, California
            Stanford University
          Jan 7, 2022

          Breast Cancer, Early-Onset Trial in United States (Neoadjuvant chemo administered before surgical extraction of a tumor,

          Active, not recruiting
          • Breast Cancer, Early-Onset
          • Neoadjuvant chemotherapy administered before surgical extraction of a tumor
          • Observational
          • Elizabeth, New Jersey
          • +11 more
          Nov 29, 2022

          Asian Multicenter Prospective Study of ctDNA Sequencing

          Recruiting
          • Cervical Cancer
          • +5 more
          • NGS analysis of ctDNA
          • Tokyo, Japan
          • +18 more
          Sep 28, 2022

          HER2-negative Metastatic Breast Cancer Trial in Paris (Chemotherapy monitoring by circulating tumor DNA analysis)

          Recruiting
          • HER2-negative Metastatic Breast Cancer
          • Chemotherapy monitoring by circulating tumor DNA analysis
          • Paris, France
            Institut Curie
          Oct 20, 2021

          Triple-negative Breast Cancer Trial in Guandong (Tislelizumab, capecitabine)

          Recruiting
          • Triple-negative Breast Cancer
          • Guandong, Guangdong, China
            Sunyat-sen Memorial Hospital
          Mar 4, 2021

          Metastatic Colorectal Cancer, No Evidence of Disease Status, ctDNA Monitoring Trial in Shanghai (ctDNA and adjuvant therapy,

          Recruiting
          • Metastatic Colorectal Cancer
          • +2 more
          • ctDNA and adjuvant therapy
          • ctDNA
          • Shanghai, Shanghai, China
            Fudan University Shanghai Cancer Center
          Nov 22, 2022

          Appendiceal Adenocarcinoma, Colorectal Trial in Houston (Circulating tumoral DNA directed neoadjuvant therapy arm)

          Not yet recruiting
          • Appendiceal Adenocarcinoma
          • Colorectal
          • Circulating tumoral DNA directed neoadjuvant therapy arm
          • Houston, Texas
            M D Anderson Cancer Center
          Jul 7, 2023

          NSCLC Trial in Beijing

          Recruiting
          • NSCLC
            • Beijing, China
              Yuyan Wang
            Oct 10, 2023

            Colorectal Cancer, Colon Cancer, Rectum Cancer Trial in Houston (Regorafenib, XmAb20717)

            Not yet recruiting
            • Colorectal Cancer
            • +2 more
            • Houston, Texas
              M D Anderson Cancer Center
            May 31, 2023

            Breast Cancer, Triple Negative Breast Cancer Trial in United States (Capecitabine, Talazoparib, Atezolizumab)

            Recruiting
            • Breast Cancer
            • Triple Negative Breast Cancer
            • Washington, District of Columbia
            • +5 more
            Jan 12, 2023

            Stage II Melanoma Trial in United States (Atezolizumab, Tiragolumab, Signatera Assay)

            Recruiting
            • Stage II Melanoma
            • Duarte, California
            • +5 more
            Nov 10, 2022

            High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation Trial in Shanghai (ctDNA

            Recruiting
            • High-risk Stage II Colorectal Cancer
            • +2 more
            • ctDNA methylation dynamic monitoring
            • Shanghai, Shanghai, China
              Fudan University Shanghai Cancer Center
            Jun 14, 2023

            Diffuse Large B Cell Lymphoma Trial in Philadelphia (Nivolumab, IV, 240 mg)

            Active, not recruiting
            • Diffuse Large B Cell Lymphoma
            • Nivolumab, IV, 240 mg
            • Philadelphia, Pennsylvania
              Fox Chase Cancer Center
            Jan 3, 2023

            Melanoma, NSCLC Trial (Evaluation of ctDNA using the F1T after 1 year of immunotherapy)

            Not yet recruiting
            • Melanoma
            • Non-small Cell Lung Cancer
            • Evaluation of ctDNA using the F1T after 1 year of immunotherapy
            • (no location specified)
            Nov 24, 2023

            Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou

            Not yet recruiting
            • Minimal Residual Disease
            • Esophageal Squamous Cell Carcinoma
              • Guangzhou, Guangdong, China
                Guangdong Provincial People's Hospital
              Jun 10, 2023